Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Metrics to compare | MRKR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRKRPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.8x | −0.6x | −0.6x | |
PEG Ratio | 0.05 | −0.02 | 0.00 | |
Price/Book | 1.1x | 1.0x | 2.6x | |
Price / LTM Sales | 2.2x | 8.7x | 3.3x | |
Upside (Analyst Target) | - | 252.3% | 39.1% | |
Fair Value Upside | Unlock | 27.2% | 5.4% | Unlock |